
TARA Stock Forecast & Price Target
TARA Analyst Ratings
Bulls say
Protara Therapeutics is positioned favorably in the oncology and rare disease markets through its lead program, TARA-002, which is demonstrating promising interim efficacy and durability data, supporting its potential as a first-mover in the BCG-naïve setting. The company’s strategy includes robust engagement with the FDA, outlining a clear registrational pathway for TARA-002, which enhances its prospects for capturing substantial market share in both the BCG-naïve and BCG-unresponsive patient populations. Additionally, the positive interim results from trials in lymphatic malformations reinforce Protara's potential for sustainable and low-risk value creation, augmenting its overall investment appeal.
Bears say
Protara Therapeutics Inc faces significant financial risks primarily due to its reliance on the successful development and commercialization of its limited portfolio, particularly TARA-002 and IV choline chloride. The company's valuation may be adversely impacted by potential regulatory hurdles, extended timelines for clinical trials, and the uncertainty of achieving commercial viability for its therapies in a competitive market. Additionally, ongoing funding requirements and potential cash flow issues could further strain the company’s financial position, raising concerns among investors regarding its long-term sustainability.
This aggregate rating is based on analysts' research of Protara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TARA Analyst Forecast & Price Prediction
Start investing in TARA
Order type
Buy in
Order amount
Est. shares
0 shares